See Editorial on Page 1877
Steatohepatitis/Metabolic Liver Disease
Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials
Article first published online: 17 OCT 2013
© 2013 by the American Association for the Study of Liver Diseases
Volume 58, Issue 6, pages 1930–1940, December 2013
How to Cite
Noureddin, M., Lam, J., Peterson, M. R., Middleton, M., Hamilton, G., Le, T.-A., Bettencourt, R., Changchien, C., Brenner, D. A., Sirlin, C. and Loomba, R. (2013), Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology, 58: 1930–1940. doi: 10.1002/hep.26455
The funding agencies did not have any role in the design or conduct of the study; in the collection, management, analysis, or interpretation of the data; or in the preparation, review, or approval of the article.
Potential conflict of interest: Dr. Sirlin consults for Bayer. Dr. Middleton received grants from Isis, Genzyme, Sanofi, Merck, GE, Siemens, Gilead, Pfizer, Synageva, Biomedical Systems, Bioclinica, Profil, and Takeda
- Issue published online: 26 NOV 2013
- Article first published online: 17 OCT 2013
- Accepted manuscript online: 20 MAY 2013 02:25PM EST
- Manuscript Accepted: 9 APR 2013
- Manuscript Received: 19 DEC 2012
- Clinical and Translational Research Institute of the University of California San Diego
- American Gastroenterological Association Foundation/Sucampo/Association of Specialty Professors Designated Research Award in Geriatric Gastroenterology
- Atlantic Philanthropies, Inc., the John A. Hartford Foundation, the Association of Specialty Professors, the American Gastroenterological Association. Grant Number: K23-DK090303
- 7The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023., , , , , , et al.
- 12A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J Hepatol 2012;57:376-383., , , , , , et al.
- 14Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol 2007;102:2716-2717., .Direct Link:
- 21T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. J Magn Reson Imaging 2011;33:873-881., , , , , , et al.
- 23Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease—MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012;36:22-29., , , , , , et al.
- 24for San Diego Integrated NAFLD Research Consortium (SINC). Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012;56:922-932., , , , , , et al.;